These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

181 related items for PubMed ID: 31412798

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial.
    Davids MS, Brander DM, Kim HT, Tyekucheva S, Bsat J, Savell A, Hellman JM, Bazemore J, Francoeur K, Alencar A, Shune L, Omaira M, Jacobson CA, Armand P, Ng S, Crombie J, LaCasce AS, Arnason J, Hochberg EP, Takvorian RW, Abramson JS, Fisher DC, Brown JR, Blood Cancer Research Partnership of the Leukemia & Lymphoma Society.
    Lancet Haematol; 2019 Aug; 6(8):e419-e428. PubMed ID: 31208944
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. High prognostic value of measurable residual disease detection by flow cytometry in chronic lymphocytic leukemia patients treated with front-line fludarabine, cyclophosphamide, and rituximab, followed by three years of rituximab maintenance.
    García-Marco JA, Jiménez JL, Recasens V, Zarzoso MF, González-Barca E, De Marcos NS, Ramírez MJ, Parraga FJP, Yañez L, De La Serna Torroba J, Malo MDG, Ariznavarreta GD, Persona EP, Guinaldo MAR, De Paz Arias R, Llanos EB, Jarque I, Valle MDCF, Tatay AC, De Oteyza JP, Martin EMD, Fernández IP, Martinez RM, Costa MAA, Champ D, Suarez JG, Díaz MG, Ferrer S, Carbonell F, García-Vela JA, GELLC Study Group.
    Haematologica; 2019 Nov; 104(11):2249-2257. PubMed ID: 30890600
    [Abstract] [Full Text] [Related]

  • 5. Time-to-progression after front-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy for chronic lymphocytic leukaemia: a retrospective, multicohort study.
    Herling CD, Coombes KR, Benner A, Bloehdorn J, Barron LL, Abrams ZB, Majewski T, Bondaruk JE, Bahlo J, Fischer K, Hallek M, Stilgenbauer S, Czerniak BA, Oakes CC, Ferrajoli A, Keating MJ, Abruzzo LV.
    Lancet Oncol; 2019 Nov; 20(11):1576-1586. PubMed ID: 31582354
    [Abstract] [Full Text] [Related]

  • 6. Immune recovery after fludarabine-cyclophosphamide-rituximab treatment in B-chronic lymphocytic leukemia: implication for maintenance immunotherapy.
    Ysebaert L, Gross E, Kühlein E, Blanc A, Corre J, Fournié JJ, Laurent G, Quillet-Mary A.
    Leukemia; 2010 Jul; 24(7):1310-6. PubMed ID: 20463751
    [Abstract] [Full Text] [Related]

  • 7. Risk adjusted therapy in chronic lymphocytic leukemia: a phase II cancer trials Ireland (CTRIAL-IE [ICORG 07-01]) study of fludarabine, cyclophosphamide, and rituximab therapy evaluating response adapted, abbreviated frontline therapy with FCR in non-del(17p) CLL.
    Appleby N, O'Brien D, Quinn FM, Smyth L, Kelly J, Parker I, Scott K, Cahill MR, Crotty G, Enright H, Hennessy B, Hodgson A, Leahy M, O'Leary H, O'Dwyer M, Hayat A, Vandenberghe EA.
    Leuk Lymphoma; 2018 Jun; 59(6):1338-1347. PubMed ID: 28925785
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Prognostic and Predictive Effect of IGHV Mutational Status and Load in Chronic Lymphocytic Leukemia: Focus on FCR and BR Treatments.
    Visentin A, Facco M, Gurrieri C, Pagnin E, Martini V, Imbergamo S, Frezzato F, Trimarco V, Severin F, Raggi F, Scomazzon E, Pravato S, Piazza F, Semenzato G, Trentin L.
    Clin Lymphoma Myeloma Leuk; 2019 Oct; 19(10):678-685.e4. PubMed ID: 31371221
    [Abstract] [Full Text] [Related]

  • 10. Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study.
    Egle A, Steurer M, Melchardt T, Weiss L, Gassner FJ, Zaborsky N, Geisberger R, Catakovic K, Hartmann TN, Pleyer L, Voskova D, Thaler J, Lang A, Girschikofsky M, Petzer A, Greil R.
    Ann Hematol; 2018 Oct; 97(10):1825-1839. PubMed ID: 29862437
    [Abstract] [Full Text] [Related]

  • 11. Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia.
    Letestu R, Dahmani A, Boubaya M, Baseggio L, Campos L, Chatelain B, Debliquis A, Drénou B, Jacob MC, Legac E, Le Garff-Tavernier M, Lhoumeau AC, Quiney C, Robillard N, Ticchioni M, Aanei C, Katsahian S, Delepine R, Vaudaux S, Rouillé V, Béné MC, Dartigeas C, Van Den Neste E, Leprêtre S, Feugier P, Cartron G, Leblond V, Lévy V, Cymbalista F, French Innovative Leukemia Organization (FILO).
    Leukemia; 2021 Jun; 35(6):1597-1609. PubMed ID: 32934355
    [Abstract] [Full Text] [Related]

  • 12. Low-dose fludarabine and cyclophosphamide combined with rituximab in the first-line treatment of elderly/comorbid patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL): long-term results of project Q-lite by the Czech CLL Study Group.
    Smolej L, Brychtová Y, Cmunt E, Doubek M, Špaček M, Belada D, Šimkovič M, Stejskal L, Zygulová I, Urbanová R, Brejcha M, Zuchnická J, Móciková H, Kozák T, Czech CLL Study Group.
    Br J Haematol; 2021 May; 193(4):769-778. PubMed ID: 33618437
    [Abstract] [Full Text] [Related]

  • 13. Impact of gene mutations and chromosomal aberrations on progression-free survival in chronic lymphocytic leukemia patients treated with front-line chemoimmunotherapy: Clinical practice experience.
    Spunarova M, Tom N, Pavlova S, Mraz M, Brychtova Y, Doubek M, Panovska A, Skuhrova Francova H, Brzobohata A, Pospisilova S, Mayer J, Trbusek M.
    Leuk Res; 2019 Jun; 81():75-81. PubMed ID: 31054420
    [Abstract] [Full Text] [Related]

  • 14. Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib.
    Wang XV, Hanson CA, Tschumper RC, Lesnick CE, Braggio E, Paietta EM, O'Brien S, Barrientos JC, Leis JF, Zhang CC, Coutre SE, Barr PM, Cashen AF, Mato AR, Singh AK, Mullane MP, Erba H, Stone R, Litzow MR, Tallman MS, Shanafelt TD, Kay NE.
    Blood; 2021 Dec 30; 138(26):2810-2827. PubMed ID: 34407545
    [Abstract] [Full Text] [Related]

  • 15. A phase II Japanese trial of fludarabine, cyclophosphamide and rituximab for previously untreated chronic lymphocytic leukemia.
    Izutsu K, Kinoshita T, Takizawa J, Fukuhara S, Yamamoto G, Ohashi Y, Suzumiya J, Tobinai K.
    Jpn J Clin Oncol; 2021 Mar 03; 51(3):408-415. PubMed ID: 33244584
    [Abstract] [Full Text] [Related]

  • 16. The absolute percent deviation of IGHV mutation rather than a 98% cut-off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab.
    Jain P, Nogueras González GM, Kanagal-Shamanna R, Rozovski U, Sarwari N, Tam C, Wierda WG, Thompson PA, Jain N, Luthra R, Quesada A, Sanchez-Petitto G, Ferrajoli A, Burger J, Kantarjian H, Cortes J, O'Brien S, Keating MJ, Estrov Z.
    Br J Haematol; 2018 Jan 03; 180(1):33-40. PubMed ID: 29164608
    [Abstract] [Full Text] [Related]

  • 17. Fludarabine, cyclophosphamide, and multiple-dose rituximab as frontline therapy for chronic lymphocytic leukemia.
    Short NJ, Keating MJ, Wierda WG, Faderl S, Ferrajoli A, Estrov Z, Smith SC, O'Brien SM.
    Cancer; 2015 Nov 01; 121(21):3869-76. PubMed ID: 26218678
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial.
    Böttcher S, Ritgen M, Fischer K, Stilgenbauer S, Busch RM, Fingerle-Rowson G, Fink AM, Bühler A, Zenz T, Wenger MK, Mendila M, Wendtner CM, Eichhorst BF, Döhner H, Hallek MJ, Kneba M.
    J Clin Oncol; 2012 Mar 20; 30(9):980-8. PubMed ID: 22331940
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.